Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine
Go back to Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine| Beam Inc. (NASDAQ: BEAM) | Delayed: 35.53 +1.39 (4.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.14 | 52 Week High | $83.60 | |||
| Open | $34.90 | 52 Week Low | $82.96 | |||
| Day High | $36.88 | P/E | 15.86 | |||
| Day Low | $34.82 | EPS | $2.24 | |||
| Volume | 2,601,469 | |||||
